Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 7, 2006, Pages 778-785

  Rini, Brian I ^a   Halabi, Susan ^b   Barrier, Robert ^b   Margolin, Kim A ^c   Avigan, David ^d   Logan, Theodore ^e   Stadler, Walter M ^f   McCarthy, Philip L ^g   Linker, Charles A ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Allogeneic; Nonmyeloablative transplant; Renal cell carcinoma

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; FK 06; FLUCONAZOLE; FLUDARABINE; FOLINIC ACID; ITRACONAZOLE; METHOTREXATE; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; UNCLASSIFIED DRUG; VALACICLOVIR; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HERPES SIMPLEX; HLA MATCHING; HUMAN; KIDNEY CARCINOMA; LIVER FAILURE; MALE; METASTASIS; MULTICENTER STUDY; MYCOSIS; NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; SEPSIS; SIBLING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; CARCINOMA, RENAL CELL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS;

EID: 33745119041     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.03.011     Document Type: Article

References (24)

1. Bukowski R.M. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 19 (2001) 148-154
2. Atkins M.B., Sparano J., Fisher R.I., et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11 (1993) 661-670
3. Negrier S., Escudier B., Lasset C., et al., Groupe Français d'Immunotherapie. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338 (1998) 1272-1278
4. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85 (1993) 622-632
5. Law T.M., Motzer R.J., Mazumdar M., et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76 (1995) 824-832
6. Figlin R.A., Thompson J.A., Bukowski R.M., et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17 (1999) 2521-2529
7. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343 (2000) 750-758
8. Rini B.I., Zimmerman T., Stadler W.M., et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy. feasibility, engraftment, and clinical results. J Clin Oncol 20 (2002) 2017-2024
9. Artz A.S., Van Besien K., Zimmerman T., et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma. the University of Chicago Experience. Bone Marrow Transplant 35 (2005) 253-260
10. Bregni M., Dodero A., Peccatori J., et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99 (2002) 4234-4236
11. Pedrazzoli P., Da Prada G.A., Giorgiani G., et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen. a pilot study in patients with refractory malignancies. Cancer 94 (2002) 2409-2415
12. Ueno N.T., Cheng Y.C., Rondon G., et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102 (2003) 3829-3836
13. Nakagawa T., Kami M., Hori A., et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma. single institution experience with a minimum 1-year follow-up. Exp Hematol 32 (2004) 599-606
14. Massenkeil G., Roigas J., Nagy M., et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma. delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 34 (2004) 309-316
15. Tykodi S.S., Warren E.H., Thompson J.A., et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning. toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 10 (2004) 7799-7811
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al., European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
17. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
18. Igarashi T., Wynberg J., Srinivasan R., et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104 (2004) 170-177
19. Culine S., Bekradda M., Kramar A., et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83 (1998) 2548-2553
20. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
21. Negrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines. a report from the Groupe Français d'Immunotherapie. Ann Oncol 13 (2002) 1460-1468
22. Escudier B., Szczylik C., Eisen T., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23 suppl (2005) 4510
23. Motzer R.J., Rini B.I., Michaelson M.D., et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23 suppl (2005) 4508
24. Rini B., Rixe O., Bukowski R., et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 23 suppl (2005) 4509